Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003120 | 0.90 | LMNA (0.50) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL1003394 | 0.89 | MEN1 (0.50) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL2375444 | 0.88 | LMNA (0.44) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL23851410 | 0.87 | KMT2A (0.43) | LMNAKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL2374888 | 0.87 | GPR119 (0.41) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL9313155 | 0.87 | CTSS (0.39) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL2373659 | 0.86 | PKM (0.52) | CYP4F2CYP4A11LMNAKMT2AMEN1 | |
| SCHEMBL5674705 | 0.84 | PKM (0.53) | KMT2AMEN1CNR1CNR2KDM1A | |
| SCHEMBL2185224 | 0.84 | KDM1A (0.46) | KMT2AMEN1CNR1CNR2KDM1A | |
| SCHEMBL3355644 | 0.82 | KMT2A (0.52) | LMNAKMT2AMEN1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2346848-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| WO-2010054968-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | CYP4F2 2339/4885CYP4A11 1592/4885LMNA 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.